Clarity Pharmaceuticals Ltd Cash Flow-to-Debt Ratio
Clarity Pharmaceuticals Ltd cash flow-to-debt ratio. Clarity Pharmaceuticals Ltd (CU6) has a Cash Flow-to-Debt Ratio of -3.45x as of June 2026, meaning its operating cash flow of AU$-44.75 Million could theoretically repay -3% of its total liabilities (AU$12.96 Million) in one year. See Clarity Pharmaceuticals Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Clarity Pharmaceuticals Ltd (2018–2026)
Cash flow-to-debt ratio of Clarity Pharmaceuticals Ltd from 2018 to 2026. Historical debt coverage capacity for Clarity Pharmaceuticals Ltd across 9 annual periods. Also explore Clarity Pharmaceuticals Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Clarity Pharmaceuticals Ltd Cash Flow-to-Debt Ratio by Year (2018–2026)
Clarity Pharmaceuticals Ltd cash flow-to-debt ratio by year from 2018 to 2026. Year-by-year debt coverage analysis for Clarity Pharmaceuticals Ltd. For the full cash flow conversion analysis, see CU6 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -7.14x | AU$-92.55 Million | AU$12.96 Million | ▼ -42.7% |
| 2025 | -5.01x | AU$-54.77 Million | AU$10.94 Million | ▲ +3.5% |
| 2024 | -5.19x | AU$-43.24 Million | AU$8.33 Million | ▼ -45.7% |
| 2023 | -3.56x | AU$-27.50 Million | AU$7.72 Million | ▼ -102.9% |
| 2022 | -1.76x | AU$-13.31 Million | AU$7.59 Million | ▲ +46.6% |
| 2021 | -3.29x | AU$-7.68 Million | AU$2.34 Million | ▲ +54.0% |
| 2020 | -7.14x | AU$-6.83 Million | AU$956.09K | ▼ -119.0% |
| 2019 | -3.26x | AU$-3.71 Million | AU$1.14 Million | ▼ -86.5% |
| 2018 | -1.75x | AU$-1.50 Million | AU$857.04K | — |